ATE382615T1 - Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung - Google Patents

Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung

Info

Publication number
ATE382615T1
ATE382615T1 AT01909008T AT01909008T ATE382615T1 AT E382615 T1 ATE382615 T1 AT E382615T1 AT 01909008 T AT01909008 T AT 01909008T AT 01909008 T AT01909008 T AT 01909008T AT E382615 T1 ATE382615 T1 AT E382615T1
Authority
AT
Austria
Prior art keywords
chromes
tocotrienols
tocopherols
side chain
chain derivatives
Prior art date
Application number
AT01909008T
Other languages
English (en)
Inventor
Robert Sanders
Kimberly Kline
Laurence Hurley
Robb Gardner
Marla Menchaca
Weiping Yu
Puthucode Ramanan
Shenquan Liu
Karen Israel
Original Assignee
Res Dev Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/502,592 external-priority patent/US6770672B1/en
Application filed by Res Dev Foundation filed Critical Res Dev Foundation
Application granted granted Critical
Publication of ATE382615T1 publication Critical patent/ATE382615T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/46—Nitrogen atoms attached in position 4 with hydrocarbon radicals, substituted by nitrogen atoms, attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/20—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 hydrogenated in the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/66—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/76—Benzo[c]pyrans

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01909008T 2000-02-11 2001-02-09 Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung ATE382615T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/502,592 US6770672B1 (en) 1998-09-23 2000-02-11 Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof

Publications (1)

Publication Number Publication Date
ATE382615T1 true ATE382615T1 (de) 2008-01-15

Family

ID=23998504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01909008T ATE382615T1 (de) 2000-02-11 2001-02-09 Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung

Country Status (14)

Country Link
US (2) US7312232B2 (de)
EP (1) EP1254130B1 (de)
JP (1) JP2004504268A (de)
KR (1) KR100847678B1 (de)
CN (1) CN1243000C (de)
AT (1) ATE382615T1 (de)
AU (2) AU2001236805B2 (de)
CA (1) CA2399802C (de)
DE (1) DE60132171D1 (de)
IL (2) IL151108A0 (de)
NZ (1) NZ520798A (de)
RU (1) RU2263672C2 (de)
WO (1) WO2001058889A1 (de)
ZA (1) ZA200206243B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6703384B2 (en) 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
AU2001236805B2 (en) 2000-02-11 2005-07-14 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
KR100612398B1 (ko) * 2000-11-14 2006-08-16 바이탈 헬스 사이언시즈 피티와이 리미티드 포스페이트 유도체의 착체
AUPR549901A0 (en) * 2001-06-06 2001-07-12 Vital Health Sciences Pty Ltd Topical formulation containing tocopheryl phosphates
JP4745608B2 (ja) * 2001-07-27 2011-08-10 バイタル ヘルス サイエンシズ プロプライアタリー リミティド 電子伝達剤のリン酸誘導体を用いた皮膚治療
CA2466536C (en) * 2001-12-13 2012-02-07 Vital Health Sciences Pty Ltd Transdermal transport of compounds
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
AU2002950713A0 (en) 2002-08-09 2002-09-12 Vital Health Sciences Pty Ltd Carrier
MXPA05007278A (es) * 2003-01-17 2005-09-30 Vital Health Sciences Pty Ltd Compuestos que tienen propiedades anti-proliferativas.
AU2003901815A0 (en) * 2003-04-15 2003-05-01 Vital Health Sciences Pty Ltd Phosphate derivatives
GB0313612D0 (en) 2003-06-12 2003-07-16 Novartis Ag Organic compounds
US20060235234A1 (en) * 2003-09-15 2006-10-19 Werner Bonrath New route to alpha-tocopherol, alpha-tocopheryl alkanoates and precursors thereof
ATE495730T1 (de) 2004-03-03 2011-02-15 Vital Health Sciences Pty Ltd Alkaloid-formulierungen
MX2007010492A (es) * 2005-03-03 2007-11-08 Vital Health Sciences Pty Ltd Compuestos que tienen propiedades anticancer.
EP2548581A3 (de) 2005-06-17 2013-02-20 Vital Health Sciences Pty Ltd. Träger mit einem oder mehreren Di- bzw. Mono-(Elektrontransfermittel) Phosphatderivaten oder Komplexen davon
BRPI0621081A2 (pt) * 2005-12-23 2011-11-29 Vital Health Sciences Pty Ltd método de modulação de uma ou mais citocinas imuno-reguladoras, uso de um ou mais derivados de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos, método de inibição de uma resposta inflamatória e/ou de estimulação de uma resposta anti-inflamatória, método de tratamento e/ou de profilaxia de distúbios imunológicos, distúrbios inflamatórios e/ou distúrbios proliferativos celulares, agente imuno-modulador, agente anti-inflamatório ou agente anti-cáncer e um ou mais derivado de fosfato de um ou mais hidróxi cromanos ou complexos dos mesmos
US20080009545A1 (en) * 2006-02-21 2008-01-10 The Ohio State University Research Foundation Anticancer agents
ES2414205T3 (es) 2006-06-02 2013-07-18 The Ohio State University Research Foundation Agentes terapéuticos para el tratamiento de linfoma de células del manto
US8288369B2 (en) * 2006-06-27 2012-10-16 University Of South Florida Delta-tocotrienol treatment and prevention of pancreatic cancer
US20100292316A1 (en) * 2007-07-18 2010-11-18 Research Development Foundation Improved therapeutic methods and compositions comprising chroman ring compounds
RU2350620C1 (ru) * 2007-07-23 2009-03-27 Институт нефтехимии и катализа РАН СПОСОБ ПОЛУЧЕНИЯ 6-O-[β-D-(2,3,4,6-ТЕТРА-O-АЦЕТИЛ)ГЛИКОПИРАНОЗИЛ]-d,l-α-ТОКОФЕРОЛОВ
CA2734208C (en) 2008-03-14 2018-01-09 Jiri Neuzil Mitochondrially delivered anti-cancer compounds
WO2010120711A1 (en) * 2009-04-13 2010-10-21 The Ohio State University Research Foundation Protein phosphatase 2a-activating agents
EP2418948B1 (de) 2009-04-17 2013-09-04 The Ohio State University Research Foundation Antihaftmittel
ES2999020T3 (en) 2010-02-05 2025-02-24 Phosphagenics Ltd Carrier comprising non-neutralised tocopheryl phosphate
RU2427323C1 (ru) * 2010-02-25 2011-08-27 Федеральное государственное учреждение "Ростовский научно-исследовательский онкологический институт Федерального агентства по высокотехнологичной медицинской помощи" Способ прогнозирования генерализации процесса при злокачественных опухолях костей
SG184181A1 (en) 2010-03-30 2012-10-30 Phosphagenics Ltd Transdermal delivery patch
WO2012074960A2 (en) 2010-11-29 2012-06-07 The Ohio State University Research Foundation Fty720-derived anticancer agents
EP2685992A4 (de) 2011-03-15 2014-09-10 Phosphagenics Ltd Aminochinoline als kinasehemmer
RU2613110C2 (ru) * 2012-05-18 2017-03-15 Те Огайо Стейт Юниверсити Способы улучшения функции печени
JP2015518896A (ja) 2012-06-06 2015-07-06 ユニザー ヴィロロジー，エルエルシー 新規イミノ糖およびそれらの用途
WO2013188490A1 (en) * 2012-06-13 2013-12-19 Cytec Technology Corp. Stabilizer compositions containing substituted chroman compounds and methods of use
AU2014318014C1 (en) * 2013-09-06 2018-11-15 Research Development Foundation Alpha-tea salt forms: compositions and uses for treating disease
CA2924126C (en) 2013-09-13 2023-05-02 The Board Of Trustees Of The University Of Arkansas Preparation and use of a composition for prevention and mitigation of the effects of radiation
US20160324914A1 (en) 2015-05-05 2016-11-10 Tocol Pharmaceuticals, Llc Use of rice bran oil distillate extract for prevention and mitigation of the effects of radiation
CN105078963B (zh) * 2015-09-29 2018-06-22 中山大学 α-生育酚在制备治疗血吸虫病药物中的应用
CN108601732A (zh) 2015-12-09 2018-09-28 磷肌酸有限公司 药物制剂
KR102647670B1 (ko) 2016-12-21 2024-03-15 아베초 바이오테크놀로지 리미티드 방법
KR20180002728U (ko) 2017-03-10 2018-09-19 주식회사 두울온돌침대 전열 매트리스
WO2022087735A1 (en) * 2020-10-28 2022-05-05 Hermay Labs Corporation Labile and coherent redox-silent analogues for vitamin e enhancement

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5118954B2 (de) * 1972-02-04 1976-06-14
CS172015B1 (de) 1974-05-12 1976-12-29
US4181725A (en) * 1977-05-02 1980-01-01 The Regents Of The University Of Michigan Method for alleviating psoriasis
WO1979000401A1 (fr) * 1977-12-16 1979-07-12 Nisshin Flour Milling Co Agent anti-tumeur
JPS6056155B2 (ja) 1978-12-04 1985-12-09 エーザイ株式会社 クロマニルオキシ脂肪酸同族体
US4457918A (en) * 1982-05-12 1984-07-03 The General Hospital Corporation Glycosides of vitamins A, E and K
DE3309159A1 (de) * 1983-03-15 1984-09-20 Basf Ag, 6700 Ludwigshafen Neue optisch aktive chromanderivate, verfahren zu deren herstellung sowie neue zwischenprodukte
US4873088A (en) * 1983-09-06 1989-10-10 Liposome Technology, Inc. Liposome drug delivery method and composition
US4617317A (en) * 1984-10-31 1986-10-14 Bennet Justin D Method of treating ulcerative colitis
JPS63500175A (ja) * 1985-05-22 1988-01-21 リポソ−ム　テクノロジ−，インコ−ポレイテツド リポソ−ム吸入法および吸入システム
US4665204A (en) * 1985-06-27 1987-05-12 Henkel Corporation Diester derivatives of tocopherol
JPS63203837A (ja) 1987-02-17 1988-08-23 日清紡績株式会社 整経機における糸パツケ−ジ交換システム
JPS63303049A (ja) 1987-06-04 1988-12-09 Shinagawa Refract Co Ltd 繊維強化ガラス質溶射材料
JPS6441727A (en) 1987-08-07 1989-02-14 Toshiba Corp Cooking unit
US5198432A (en) 1988-01-29 1993-03-30 Center For Innovative Technology Method of preventing chlorohydrocarbon toxicity using sterol derivatives
US5610180A (en) * 1988-01-29 1997-03-11 Virginia Commonwealth University Ionizable congeners of aromatic and aliphatic alcohols as anti-leukemia agents
US5260294A (en) * 1988-08-09 1993-11-09 Hoffman-La Roche Inc. Chromanes and their pharmaceutical compositions and methods
JPH02215778A (ja) * 1989-02-14 1990-08-28 Kuraray Co Ltd ３，４―ジヒドロ―２ｈ―ベンゾピラン誘導体及びその医薬用途
JPH03206089A (ja) 1990-01-05 1991-09-09 Eisai Co Ltd 新規ビタミンｅ誘導体及びその製造方法
DE4014708C2 (de) 1990-05-08 1994-03-10 Heidelberger Druckmasch Ag Verfahren zum Ermitteln von Registerfehlern
US5114957A (en) * 1990-05-08 1992-05-19 Biodor U.S. Holding Tocopherol-based antiviral agents and method of using same
FR2672601B1 (fr) 1991-02-08 1994-10-14 Synthelabo Derives de benzo-1,5-thiazepine, leur preparation et leur application en therapeutique.
JPH05213982A (ja) 1991-03-26 1993-08-24 Dainippon Ink & Chem Inc オリゴ糖トコフェロール配糖体及び硫酸化オリゴ糖トコフェロール配糖体並びにこれを有効成分とする抗ウイルス剤
FR2676056B1 (fr) * 1991-05-03 1993-07-16 Adir Nouveaux derives du benzopyranne leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
EP0636618A1 (de) 1991-06-04 1995-02-01 Marigen S.A. Spontan dispergierbare Konzentrate und Mikroemulsionen mit Vitamin-E-Verbindungen zur Herstellung von Arzneimitteln mit Antitumoraler Wirksamkeit
US5135945A (en) * 1991-06-05 1992-08-04 Merrell Dow Pharmaceuticals Inc. Cholesterol-lowering tocopherol analogs
CA2124086A1 (en) * 1991-11-22 1993-05-27 Ronald H. Lane Tocotrienols and tocotrienol-like compounds and methods for their use
RU2098416C1 (ru) * 1992-03-17 1997-12-10 Басф Аг Способ получения dl-альфа-токоферола или его ацетата
US5545660A (en) * 1992-04-07 1996-08-13 Merrell Pharmaceuticals Inc. Hydrazide derivatives of 3,4-dihydro-2H-1-benzopyrans
DE4215536A1 (de) * 1992-05-12 1993-11-18 Basf Ag Cyan-Mischungen für den Farbstofftransfer
FR2695387B1 (fr) * 1992-09-09 1994-10-21 Adir Nouveaux composés benzopyraniques, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
US5403834A (en) * 1992-12-07 1995-04-04 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
IT1256264B (it) * 1992-12-31 1995-11-29 Lifegroup Spa N-acilderivati di idrossiammine dotati di attivita' scavenger ed utilizzabili nelle patologie acute e croniche correlate a fenomeni di perossidazione ed infiammazione
DE4304303C2 (de) 1993-01-22 1997-01-30 Pacific Corp Vitamin-E-Derivate mit einem quartären Stickstoffatom, Verfahren zu deren Herstellung und kosmetische Mittel enthaltend dieselben
GB9301611D0 (en) * 1993-08-04 1993-08-04 Parisella Gerald Dexterity game
CA2152693A1 (en) * 1994-08-05 1996-02-06 Kazumi Ogata Therapeutic composition for pancreatitis
US5670255A (en) * 1995-01-23 1997-09-23 Ppg Industries, Inc. Antioxidant compositions for coating substrates, substrates coated with the same and methods for inhibiting the oxidation of such compositions applied to a substrate
DE19504398A1 (de) * 1995-02-10 1996-08-14 Beiersdorf Ag Tocopherylglycoside, ihre Herstellung sowie ihre Verwendung als Tenside, als Antioxidantien sowie als der Zellalterung vorbeugender Wirkstoff in kosmetischen oder pharmazeutischen Zubereitungen
DE19523079A1 (de) 1995-06-26 1997-01-02 Basf Ag Ester und Amide der 9(Z)-Retinsäure
CA2179940A1 (en) 1995-07-18 1997-01-19 Kazumi Ogata Antiallergic composition comprising a phosphoric diester compound
US5798356A (en) 1995-08-07 1998-08-25 Alcon Laboratories, Inc. Angiostatic compounds
CA2186654A1 (en) 1995-10-13 1997-04-14 Masayuki Nakamura Phosphoric diester
JPH09301953A (ja) * 1996-03-12 1997-11-25 Sanwa Kagaku Kenkyusho Co Ltd マロン酸ジアミド誘導体及びその用途
JPH104489A (ja) * 1996-04-19 1998-01-06 Nikon Corp 画像入力装置
JPH09301969A (ja) * 1996-05-15 1997-11-25 Fuji Photo Film Co Ltd クロマン系化合物及びそれを使用する感熱記録材料
DK0815858T3 (da) * 1996-07-01 2001-10-08 Nisshin Flour Milling Co Farmaceutisk præparat, der indeholder 9-cis-retinsyre-alfa-tocopherolester, til behandling af leukæmi
US6022560A (en) * 1996-08-27 2000-02-08 Clarion Pharmaceuticals Inc. Pharmaceutical compositions, novel uses, and novel form of α-tocopherylphosphocholine
FR2754713B1 (fr) 1996-10-22 1999-01-08 Roc Sa Utilisation de complexes pour la preparation de compositions pour le traitement des peaux sensibles, procede de preparation et compositions hypoallergeniques
IL131628A0 (en) * 1997-03-04 2001-01-28 Wisconsin Alumni Res Found Method of suppressing tumor growth with combinations of isoprenoids and statins
CA2220541A1 (en) 1997-11-07 1999-05-07 Mcgill University Analogs of vitamin e
US5917060A (en) * 1997-12-17 1999-06-29 Basf Aktiengesellschaft Preparation of chromanyl derivatives
RU2232758C2 (ru) * 1998-09-23 2004-07-20 Рисерч Дивелопмент Фаундейшн Токоферолы, токотриенолы и другие производные хромана и боковых цепей и способы лечения с их использованием
US6703384B2 (en) * 1998-09-23 2004-03-09 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US6770672B1 (en) * 1998-09-23 2004-08-03 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
FR2784988B1 (fr) * 1998-10-23 2002-09-20 Adir Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US5990322A (en) * 1999-03-09 1999-11-23 Sk Corporation Alpha-tocopherol cyclopropylates, the new vitamin E derivatives and method for producing the same
US6127382A (en) * 1999-08-16 2000-10-03 Allergan Sales, Inc. Amines substituted with a tetrahydroquinolinyl group an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
AU2001236805B2 (en) * 2000-02-11 2005-07-14 Research Development Foundation Tocopherols, tocotrienols, other chroman and side chain derivatives and uses thereof
US20030236301A1 (en) * 2001-12-19 2003-12-25 Bob Sanders Liposomal delivery of vitamin E based compounds
US7045324B2 (en) * 2002-04-19 2006-05-16 Research Development Foundation Tocopherol associated protein and uses thereof

Also Published As

Publication number Publication date
US7608638B2 (en) 2009-10-27
ZA200206243B (en) 2009-10-28
US20040235938A1 (en) 2004-11-25
IL151108A0 (en) 2003-04-10
JP2004504268A (ja) 2004-02-12
RU2263672C2 (ru) 2005-11-10
RU2002124135A (ru) 2004-01-10
CA2399802C (en) 2009-12-08
AU3680501A (en) 2001-08-20
CN1529701A (zh) 2004-09-15
KR20030005186A (ko) 2003-01-17
AU2001236805B2 (en) 2005-07-14
EP1254130A4 (de) 2003-04-23
US20080119514A1 (en) 2008-05-22
KR100847678B1 (ko) 2008-07-23
EP1254130B1 (de) 2008-01-02
DE60132171D1 (de) 2008-02-14
WO2001058889A1 (en) 2001-08-16
IL151108A (en) 2006-08-01
CN1243000C (zh) 2006-02-22
US7312232B2 (en) 2007-12-25
EP1254130A1 (de) 2002-11-06
CA2399802A1 (en) 2001-08-16
NZ520798A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
ATE382615T1 (de) Tocopherole, tocotrienole, andere chrome und seitenketten-derivate und ihre verwendung
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
BG106390A (en) Novel spiro compounds
PT778277E (pt) Derivados heterociclicos substituidos como antagonistas do crf
DK1392666T3 (da) Biologisk aktive methylenblåt-derivater
ES2053609T3 (es) Derivados de urea inhibidores de lipoxigenasa.
PT1453512E (pt) Derivados de acetileno tendo actividade antagonistica do mglur 5
ATE248824T1 (de) Substituierte phenylderivate, ihre herstellung und verwendung
DE69716925D1 (de) Isoxazoline derivate und ihre verwendung als antimikroben
DE69821530D1 (de) Dihydrobenzifurane
TR200000907T2 (tr) Nötrofil elastaz inhibitörleri olarak pirolopirolon türevleri.
ATE327979T1 (de) Pyrazolinon-derivate
BG101221A (bg) N-заместени азабициклохептанови производни, приложими като невролептици
DE69529680D1 (de) 2',5'-phosphorthioat/phosphodiester-oligoadenylate und ihre antiviralen verwendungen
DE60106277D1 (de) Katalysatoren
TR199801902A2 (xx) S�lfonamid ile s�bstit�e edilmi� kromanlar, bunlar� i�eren farmakolojik bile�imler.
EP0641768A4 (de) Nitroxyalkylamid-derivate.
DE59200787D1 (de) 6-Thiono-5,6-dihydro-dibenz[b,e]azepin-11-on-11-oxime und ihre Verwendung als retrovirale Mittel.
DE60113686D1 (de) 4,5-dihydro-2-thiazolylaminderivate und ihre verwendung als no-synthase inhibitoren
DE69912306D1 (de) 1,4-diaryl-2-fluor-1-buten-3-ol-verbindungen und ihre verwendung in der herstellung von 1,4-diaryl-2-fluor-1,3-butadien- und 1,4-diaryl-2-fluor-2-buten-verbindungen
DE59905342D1 (de) N-substituierte azabicycloheptan-derivate, ihre herstellung und verwendung
ATE293605T1 (de) Fluorierte 3,4-dihydrochinolin-derivative als nos-inhibitoren
ATE301655T1 (de) Triazatrinaphthyrinen und ihre verwendung
ECSP003624A (es) Nuevos compuestos espiro

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties